XML 40 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders’ Equity (Tables)
 9 Months Ended
Sep. 29, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocated Employee Stock-Based Compensation Expense
We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Research and development$12,438 $16,438 $25,279 $34,886 
Selling, general and administrative28,040 20,899 56,760 46,832 
Total stock-based compensation expense$40,478 $37,337 $82,039 $81,718 
Stock-based compensation expense for each type of award under our equity incentive plans and ESPP were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Stock options$1,882 $3,299 $5,966 $10,470 
RSUs18,440 22,233 50,804 54,234 
PSUs19,463 11,331 22,129 14,621 
ESPP693 474 3,140 2,393 
Total stock-based compensation expense$40,478 $37,337 $82,039 $81,718 
Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $26.05 per share for the 2023 TSR-based RSUs:
Fair value of Exelixis common stock on grant date
$19.48 
Expected volatility
40.26 %
Risk-free interest rate
3.75 %
Dividend yield
— %